《新股消息》諾輝健康(06606.HK)公開超購4,132倍及上限定價 一手中籤率2%
諾輝健康-B(06606.HK)公布招股結果,計劃發行7,659.8萬股,原先約10%為本地公開發售,公開發售錄超購4,132.19倍,經重新分配後,公開發售股數增至50%。國際發售初步提呈發售的發售股份獲大幅超額認購,相當於國際發售初步
可供認購總數約64.16倍。
每股發售價定於26.66元,為上限定價(招股價介乎每股22.7至26.66元),一手500股中籤率僅2%。該股將於明日(2月18日)掛牌上市,聯席保薦人為高盛及瑞銀。
是次招股引入16名基石投資者,包括景順、清池資本、博裕、GIC、加皇環球資產管理、Columbia Funds、駿利亨德森資產管理、Rock Springs Capital Master Fund LP、Worldwide Healthcare Trust PLC、禮來亞洲旗下LAV Amber Limited、Cormorant Global、HBC Asia Healthcare Opportunities VII LLC、Octagon Investments Master Fund LP、Sage Partners Master Fund、南方基金管理及E Fund,佔公司緊隨全球發售完成後已發行股本約8.63%。
公司預計,所得款項淨額約為18.99億元,當中約40%用於為產品「常衛清」的商業化及進一步開發提供資金;約30%用於為正在進行及計劃進行的早期階段管線產品研發提供資金;約15%將用於潛在收購或外部引進癌症篩查領域的候選產品;約5%用於為產品「噗噗管」的持續銷售及營銷提供資金;以及約10%為一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.